Immunohistochemical detection of bcl-2 and p53 proteins and apoptosis in soft tissue sarcoma: Their correlations with prognosis

Oncology (Switzerland)

Volumn 54, Issue 3, 1997, Pages 238-244

  Nakanishi, Hirofumi ^a   Ohsawa, Masahiko ^a   Naka, Norifumi ^a   Uchida, Atsumasa ^a   Ochi, Takahiro ^a   Aozasa, Katsuyuki ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Apoptosis; Bcl 2; p53; Prognostic factors; Soft tissue sarcoma

Indexed keywords

CELL PROTEIN; PROTEIN BCL 2; PROTEIN P53;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CHROMOSOME NOR; ETIOLOGY; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; MULTIVARIATE ANALYSIS; NECROSIS; NEUROGENIC TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SOFT TISSUE SARCOMA; SURVIVAL RATE; SURVIVAL TIME; SYNOVIAL SARCOMA; TRUNK; TUMOR CELL; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; APOPTOSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; SARCOMA; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030993852     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227695     Document Type: Article

References (36)

1. Enzinger FM, Weiss SM: Soft tissue tumors, St, Louis, Mosby, 1994.
2. Russel WO, Cohen J, Enzinger FM, Hajdu SI, Heise H, Martin RG, et al: A clinical and pathological staging system for soft tissue sarcoma, Cancer 1977;40:1562-1570.
3. Costa J, Wesley RA, Glatstein E, Rosenberg SA: The grading of soft tissue sarcomas: Results of a clinicohistopathologic correlation in a series of 163 cases, Cancer 1984:53:530-541.
4. Trojani M, Contesso G, Coindre JM, Roussc J, Bui NB, Mascarel A, et al: Soft-tissue sarcomas of adults: Study of pathological prognostic variables and definition of a histopathological grading system, Int J Cancer 1984:33:37-42.
5. Tomita Y, Aozasa K, Myoui A, Kuratsu S, Uchida A, Hamada H, et al: Histological grading in soft-tissue sarcomas, An analysis of 164 cases including AgNOR count and mast-cell count, Int J Cancer 1993:54:194-199.
6. Kuratsu S, Aozasa K, Myoui A, Tsujimoto M, Ueda T, Uchida A, et al: Prognostic significance of argyrophilic nuclcar-organizer staining in soft-tissue sarcomas, Int J Cancer 1991; 48:211-214.
7. Triche TJ: Molecular biological aspects of soft tissue tumors, Curr Top Pathol 1995:89:47-72.
8. Isobe M, Emanuel BS, Givol D, Oren M, Croce CM: Localization of gene for human p53 tumor antigen to band 17p 13, Nature 1986:320:84-85.
9. Drobnjak M, Latres E, Pollack D, Karpch M, Dudas M, Woodruff JM, et al: Prognostic implications of p53 nuclear overexpression and high proliferation index of Ki-67 in adult soft-tissue sarcomas, J Natl Cancer Inst 1994:86: 549-554.
10. Toffoli G, Doglioni C, Cemigoi C, Frustaci S, Perin T, Canal B, et al: p53 overexprcssion in human soft tissue sarcomas: Relation to biological aggressiveness, Ann Oncol 1994;5:167-172.
11. Andrcasscn A, Oyjord T, Hovig E, Holm R, Florenes VA, Nesland JM, et al: p53 abnormalities in different subtypes of human sarcomas, Cancer Res 1993;53:468-471.
12. Soini Y, Vahakangas K, Nuorva K, Kamel D, Lane DP, Paakko P: p53 immunohistochemis-try in malignant fibrous histiocytomas and other mesenchymal tumors, J Pathol 1992:168: 29-33.
13. Toguchida J, Yamaguchi T, Ritchie B, Beauchamp RL, Dayton SH, Herrera GE, et al: Mutation spectrum of the p53 gene in bone and soft tissue sarcomas, Cancer Res 1992:52: 6194-6199.
14. Stratton MR, Moss S, Warren W, Patterson H, Clark J, Fisher C, et al: Mutation of the p53 gene in human soft tissue sarcomas: Association with abnormalities of the RBI gene, Oncogene 1990:5:1297-1301.
15. Castresana JS, Rubio MP, Gomez L, Krcic-bergs A, Zetterberg A, Barrios C: Detection of TP53 gene mutations in human sarcomas, Eur J Cancer 1995;31 A:735-738.
16. Vojtesek B, Bartek J, Lane DP: An immunochemical mapping of the human nuclear phos-phoprotein p53, New monoclonal antibodies and epitope mapping using recombinant p53, J Immunol Methods 1992;151:237-244.
17. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM: Cloning of the chromosome breakpoint of neoplastic B cells with the t(14; 18) chromosome translocation, Science 1984:226: 1097-1099.
18. Bissonnette RP, Echevcrri F: Apoptotic cell death induced by c-myc is inhibited by bcl-2, Nature 1992:359:552-554.
19. Vialc G, Roncalli M, Grimelius L, Graziani D, Wilander E, Johansson H, et al: Prognostic value of bcl-2 immunoreactivitv in medullary thyroid carcinoma, Hum Pathol 1995;26:945-950.
20. Hellemans P, van Dam PA, Weyler J, van Oos-terom AT, Buytaert P, van Marck E: Prognostic value of bcl-2 expression in invasive breast cancer, Br J Cancer 1995:72:354-360.
21. Krajcwski S, Chatten J, Hanada M, Reed JC: Immunohistochcmical analysis of the Bcl-2 oncoprotein in human neuroblastomas, Comparisons with tumor cell differentiation and N-Myc protein, Lab Invest 1995:72:42-54.
22. Joensuu H, Pylkkancn L, Toikkanen S: Bcl-2 protein expression and long-term survival in breast cancer, Am J Pathol 1994; 145:1191-1198.
23. Soini Y, Paakko P: Bcl-2 is preferentially expressed in tumours of muscle origin but is not related to p53 expression, Histopathologv 1996;28:141-145.
24. Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation, J Cell Biol 1992:119:493-501.
25. Enncking WM, Spanicr SS, Goodman MA: A system for the surgical staging of musculoskeletal sarcoma, Clin Orthop 1980:153:106-120.
26. Cordell JL, Falini B, Erbcr WN, Ghosh AK, Abdulaziz Z, Macdonald S, et al: Immunoenzy-matic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complex), J Hislochem Cytochem 1984;32:219-222.
27. Kaplan EL, Meier P: Non-paramctric estimation from incomplete observations, J Am Stat Assoc 1958;53:457-481.
28. Cox DR: Regression models and life-tables, J R StatSoc 1972:34:187-220.
29. Yonish-Rouach E, Grunwald D, Wilder S, Kimcchi A, May E, Kawrencc JJ, et al: p53-mediated cell death: Relationship to cell cycle control, Mol Cell Biol 1993; 13:1415-1423.
30. Grccnblatt MS, Bennett WP, Hollstcin M, Harris CC: Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis, Cancer Res 1994:54:4855-4878.
31. Porter PL, Gown AM, Kramp SG, Coltrera MD: Widespread p53 overexprcssion in human malignant tumors, An immunohistochcmical study using methacarn-fixcd, embedded tissue, Am J Pathol 1992:140:145-153.
32. Marie SA, Ollc S, Sie S, Lilianne F, Xiao-Feng S, John JM, et al: Cellular accumulation of p53 protein: An independent prognostic factor in stage 2 breast cancer, Eur J Cancer 1994:30: 175-180.
33. Silvano B, Giuseppe V, Paola B, Marco M, Guido C, John JM, et al: Cytoplasmic accumulation of p53 protein: An independent prognostic indicator in colorectal adenocarcinomas, J Natl Cancer Inst 1994:86:681-687.
34. Reed JC: Bcl-2 and the regulation of programmed cell death, J Cell Biol 1994;124:1-6.
35. Tormanen U, Eerola AK, Rainio P, Vahakangas K, Soini Y, Sormunen R, et al: Enhanced apoptosis predicts shortened survival in nonsmallcell lung carcinoma, Cancer Res 1995:55: 595-602.
36. Boise LIL, Gonzalez-Garcia M, Postema CE, Ding L, Lindstcin T, Turaka LA, et al: bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death, Cell 1993:74: 597-608.